J Obes Metab Syndr 2021; 30(2): 81-92
Published online June 30, 2021 https://doi.org/10.7570/jomes21022
Copyright © Korean Society for the Study of Obesity.
Bo-Yeon Kim1, Seon Mee Kang2, Jee-Hyun Kang3, Seo Young Kang4, Kyoung Kon Kim5, Kyoung-Bae Kim6, Bomtaeck Kim7, Seung Jun Kim8, Yang-Hyun Kim9, Jung-Hwan Kim10, Jae Hyun Kim11, Eun Mi Kim12, Ga Eun Nam9, Ji Yeon Park13, Jang Won Son14, Yun-A Shin15, Hye-Jung Shin16, Tae Jung Oh17, Hyug Lee18, Eon-Ju Jeon19, Sochung Chung20, Yong Hee Hong21, Chong Hwa Kim22,* ; Committee of Clinical Practice Guidelines, Korean Society for the Study of Obesity (KSSO)
1Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon; 2Department of Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan; 3Department of Family Medicine, Konyang University Hospital, Konyang University College of Medicine, Daejeon; 4International Healthcare Center, Asan Medical Center, Seoul; 5Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon; 6Department of Physical Education, Korea Military Academy, Seoul; 7Department of Family Practice and Community Health, Ajou University School of Medicine (AUSOM); 8Department of Psychiatry, Konyang University College of Medicine, Daejeon; 9Department of Family Medicine, Korea University College of Medicine, Seoul; 10Department of Family Medicine, Eulji Hospital, Eulji University School of Medicine, Seoul; 11Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; 12Department of Dietetics, Kangbuk Samsung Hospital, Seoul; 13Department of Surgery, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu; 14Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary’s Hospital, College of Medicine, The Catholic University of Korea, Bucheon; 15Department of Prescription and Rehabilitation of Exercise, College of Sport Science, Dankook University, Cheonan; 16Department of Pediatrics, National Medical Center, Seoul; 17Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam; 18Central St’ Mary’s Clinic Internal Medicine, Seoul; 19Division of Endocrinology and Metabolism, Department of Internal Medicine, Catholic University of Daegu School of Medicine, Daegu; 20Department of Pediatrics, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul; 21Department of Pediatrics, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon; 22Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, Korea
Chong Hwa Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, 28 Hohyeon-ro 489beon-gil, Sosa-gu, Bucheon 14754, Korea
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Obesity is a prevalent and complex disease. The prevalence of obesity in Korea increased from 29.7% in 2010 to 35.7% in 2018, with the prevalence of abdominal obesity being 23.8% in 2018. Obesity contributes to medical costs and socioeconomic burden due to associated comorbidities. The treatment and management of obesity is changing based on new clinical evidence. The 2020 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea summarizes evidence-based recommendations and treatment guidelines.
Keywords: Obesity, Clinical practice guidelines, Korea
The Korean Society for the Study of Obesity (KSSO) published a 2019 Obesity Fact Sheet based on data from the Korean National Health Insurance Service, which stated that the prevalence of obesity in Korea increased from 29.7% in 2010 to 35.7% in 2018. The prevalence of abdominal obesity among Korean adults in 2018 was 23.8% (28.1% for men and 18.2% for women), indicating a steady increase from 19.0% in 2009.1 Obesity is associated with metabolic abnormalities such as type 2 diabetes, dyslipidemia, insulin resistance, metabolic syndrome, gallbladder disease, coronary artery disease, hypertension, and cancer. There is an increased risk of comorbidities (directly linked with obesity) such as arthritis, back pain, and sleep apnea. Therefore, obesity is associated with medical and socio-economic burdens due to comorbidities. In addition, the treatment and management of obesity is changing, reflecting new clinical evidence.
The revised 2020 Obesity Treatment Guidelines (7th edition) was based on the previous 2018 Obesity Treatment Guidelines (6th edition),2 and included the latest research results. Levels of evidence and a variety of clinical situations were taken into account when formulating the recommended grades. In addition, changes and developments in the 2019 anti-obesity drug market were reflected in the revised guidelines.
This treatment guideline was organized into questions divided into nine major topics with the goal of increasing utilization in clinical practice among primary care physicians treating obese patients. The new revised guidelines summarize evidence-based recommendations and treatment guidelines. The levels of evidence were classified into A, B, C, and D (Table 1). The standards of the recommended grade were presented using a modified Grading of Recommendation Assessments, Development and Evaluation (GRADE) method3 and the grades were divided into classes I, IIa, IIb, and III. Recommendations with low levels of evidence, but clear benefits or high utilization rates in treatment according to user opinion survey results, were partially upgraded with the agreement of the treatment guidelines committee. In order to determine the strengths of recommendations, factors such as the level of evidence, the level of use at primary care sites reflecting benefits and risks, practicability, and acceptance were comprehensively considered (Table 1).
In this article, we introduce and briefly describe the 2020 Korean Society for the Study of Obesity (KSSO) Guideline for the Management of Obesity in Korea.
This clinical practice guideline informs the arc of the patient journey and the approach for clinical management of obesity in the primary care setting. The guideline recommendations are shown in Table 2 and include nine major themes: evaluation before obesity treatment, behavioral therapy, physical activity, nutrition therapy, pharmacotherapy, bariatric surgery, obesity in the elderly, obesity in children and adolescents, and metabolic syndrome. The purpose of the guideline is as follows. First, it helps practitioners, who are the main users of the guideline, to make safer and more effective decisions by providing evidence-based recommendations with clear evidence levels and benefits. Second, it provides high-quality evidence-based information for primary care physicians.
Diagnosis of obesity is important in the evaluation stage before obesity treatment. Body mass index (BMI), which is a value obtained by dividing body weight (kg) by the square of height (m2), is highly correlated with body fat mass, and because BMI can be used to evaluate health risks such as morbidity and mortality of obesity-associated diseases, BMI is the most commonly used index to diagnose obesity. The World Health Organization (WHO) defines obesity as BMI ≥30 kg/m2. However, East Asians, including Koreans, have increased risk of diabetes and cardiovascular disease even below BMI of 25 kg/m2 and higher abdominal fat and body fat percentages than Westerners at the same BMI.4 There is concern that the general WHO definition of obesity underestimates health risks associated with obesity in East Asians. The classification of obesity into classes I, II, and III relies on adult BMI in accordance with WHO guidelines for the Asia-Pacific region.5 Class I obesity is defined as BMI 25.0 to 29.9 kg/m2, class II obesity is defined as BMI 30.0 to 34.9 kg/m2, and class III obesity was newly defined in 2018 as ≥35.0 kg/m2 (Table 3).
Waist circumference (WC) is highly associated with intra-abdominal fat.6 WC is measured in the horizontal plane midway between the superior iliac crest and the lower margin of the last rib.7 According to the KSSO, abdominal obesity in Koreans is defined as WC ≥90 cm in men and ≥85 cm in women (Table 3). In the case of abdominal obesity, the morbidity and mortality of metabolic syndrome, diabetes, and coronary artery disease increase independently of BMI, so it is necessary to increase the risk of comorbidities classified by BMI to the next level (Table 3).
In some obese patients, secondary obesity is caused by genetic and congenital disorders, drugs, neurological and endocrine disorders, and psychiatric disorders.8 In patients with secondary obesity, relatively effective weight loss can be expected after accurate identification of the cause, so discerning secondary obesity is very important. Obesity causes metabolic abnormalities as well, and even if metabolic abnormalities are not present, obesity itself causes complications. Therefore, it is necessary to evaluate the comorbidities of obesity when treating obese patients.
To lose weight, it is necessary to reduce energy intake. Many weight control programs prescribe low-calorie diets that reduce energy intake by 500–1,000 kcal, in which case a weight loss effect of 0.5–1.0 kg per week is expected.9 Therefore, based on the results of several studies, a low-calorie diet that reduces energy intake by 500–1,000 kcal per day can bring about weight loss without negative health effects and is also relatively easy to follow. Limiting total energy intake is important for the treatment of obesity, but there is a continuing interest in the effects of dietary macronutrients, especially carbohydrate composition, on weight loss. In the early 2000s, some randomized controlled studies reported that low-carb diets resulted in greater initial weight loss than traditionally recommended low-fat diets.10 The definition of a low-carbohydrate diet is not clear and varies according to researchers, but diets with daily carbohydrate intake of more than 130 g and less than 45% of total energy are classified as low-carbohydrate diets, while diets with a daily carbohydrate intake of less than 130 g are sometimes classified as very-low carbohydrate diets.11 Several studies indicated that low carbohydrate diets resulted in significantly greater weight loss during the initial 6 months compared to control diets.10,12,13 This difference from the control group persisted at 1 year, but compared to the initial 6 months, the difference was reduced.14-16
Increasing total fat intake through a very-low carbohydrate diet is likely to be accompanied by increased intake of saturated fatty acids and trans-fatty acids, and several studies report that such intake has negative effects on vasodilating capacity at the initiation of very-low carb diets.17-19 Adhering to a low-carb diet can be considered a method of weight loss, but is not effective in the long term and may negatively affect cardiovascular health, so it is necessary to pay special attention to fatty acid composition.
Consistently limiting energy intake can help in losing weight, but many individuals find it difficult to follow a strict energy-restricted diet.19 Interest in intermittent fasting as an alternative to sustained energy-restricted diets has increased. Intermittent fasting has many forms. Meta-analyses of intermittent fasting and time-limited diets suggest that these dietary methods can result in levels of weight loss effect equivalent to those accomplished via continuous energy-restricted diet, but related studies, especially regarding long-term effects, are insufficient. There is limited evidence to include intermittent fasting as a method of dietary treatment, and further studies are needed. The KSSO guidelines summarize the characteristics of each dietary treatment.20
Exercise and physical activity are important factors in lifestyle interventions for weight loss. The weight loss effect of exercise rarely exceeds 5%, but exercise and physical activity reduce the risks associated with various metabolic factors such as weight, body fat percentage, and visceral fat, and improves lean mass and functional ability.21,22 In addition, exercise with nutrition therapy has been found to be more effective than nutrition therapy alone, or exercise without nutrition therapy.23
In individuals with no cardiovascular, metabolic, or kidney disease, and no signs or symptoms, there is no need for medical permission before prescribing exercise for either regular exercise participants or non-participants.24 In accordance with the exercise guidelines, non-participants in regular exercise can start with low and moderate intensity exercise, while regular exercise participants may begin with moderate and high intensity exercise and gradually increase exercise intensity. Regular exercise participants with underlying cardiovascular (heart, peripheral artery, or cerebrovascular) disease, metabolic disease (type 1 or type 2 diabetes), or kidney disease, but who are asymptomatic, do not need medical permission to engage in moderate intensity exercise. Medical permission is recommended prior to high-intensity exercise.24
Aerobic exercise is an essential tool in weight loss programs addressing obesity. It is recommended to perform moderate-intensity exercise at least 150 minutes per week, 3–5 times a week, starting with low-intensity exercise and gradually increasing the intensity and amount of exercise according to individual fitness level. Resistance training should be prescribed in a weight loss exercise program to increase lean mass and promote body fat loss, and it is recommended to perform exercise using large muscle groups 2–4 times a week.25
Behavior therapy can be applied not only as a programmed behavior intervention for weight control, but also for the purpose of changing behaviors related to food intake and physical activity. Treating obesity has long been known to be more effective when lifestyle interventions including behavioral therapy are performed. Therefore, all obese people should undergo behavioral therapy, along with nutrition therapy and increased physical activity. Specific methods used in behavioral therapy include self-monitoring, reinforcement, stimulus control, alternative behavior, and cognitive reconstruction.
When treating obesity, it is very important to diagnose and treat any eating disorders that may exist. Eating disorders should be considered when binge eating, weight control behaviors to offset the effects of binge eating, and excessive emphasis on weight or body shape are observed in obese people. Obese people with eating disorders benefit from psychological therapies such as guided self-help or cognitive behavior therapy focused on eating disorders.26
When treating obesity, smoking and alcohol consumption must be reduced. Obese people should be advised to quit smoking.27 Alcohol has a high caloric content of about 7.1 kcal per gram, and the liver produces fat in trace amounts.28,29 In addition, most ingested alcohol is converted to acetate, which interferes with peripheral fat breakdown and utilization. Clinically, alcohol raises blood pressure, and excessive drinking increases the risk of hypertriglyceridemia, insulin resistance, type 2 diabetes, metabolic syndrome, and abdominal obesity. Therefore, controlling excessive drinking is important for the prevention and control of obesity and metabolic syndrome.30
The basic treatments for obesity are nutrition therapy, physical activity, and behavior therapy. We recommend pharmacotherapy as an additional treatment alongside comprehensive lifestyle intervention. According to the KSSO guideline, pharmacotherapy should be considered when non-pharmacotherapy-treated patients with BMI ≥25 kg/m2 fail to lose weight (Fig. 1). Not all obese people respond to obesity drugs, and there are a significant number of non-responders. A commonly used criterion for predicting treatment response is weight loss of 5% or more within the initial 3 months. If there is no weight loss of more than 5% within 3 months of initiating the drug, pharmacotherapy should be changed or discontinued.
As of 2020, four types of obesity treatments have been approved for long-term administration in Korea: orlistat (Xenical), naltrexone-bupropion (Contrave), liraglutide (Saxenda), and phentermine-topiramate (Qsymia).31 These drugs have been approved for use in the treatment of obesity based on the results of clinical studies on long-term use. Lorcaserin (Belviq) was used as a treatment for obesity from February 2015 to February 2020, but due to increased risk of cancer, it was voluntarily withdrawn from the market in the Unites States and discontinued from sales in Korea.32 These four drugs induce significant weight loss when administered together with lifestyle modifications, and result in improvement and prevention of various complications. Anti-obesity drugs must be prescribed according to the characteristics of each patient, and the presence of other comorbidities is important when choosing drugs. Table 4 guides the selection of anti-obesity drugs according to comorbidities.
According to the International Federation for the Surgery of Obesity and Metabolic Disorders, Asian Pacific Chapter Consensus statements 2011(IFSO-APC consensus statements),33 the indications of bariatric surgery are failure to lose weight due to nonsurgical treatment in patients with BMI ≥35 kg/m2 or BMI ≥30 kg/m2 and obesity-related comorbidities, and this indication is applied in Korea. In Korea, from January 2019, the national health insurance plan has covered bariatric surgery performed for the purpose of treatment in patients with severe obesity. In patients with BMI ≥35 kg/m2 or BMI ≥30 kg/m2 and obesity-related comorbidities, health insurance benefits are applied.
Types of bariatric surgery can be largely divided into restrictive surgery, malabsorptive surgery, and combined surgery. Restrictive surgeries include sleeve gastrectomy and adjustable gastric banding, and malabsorptive surgery is defined as biliopancreatic diversion/duodenal switch (Table 5). The typical combined surgery is Roux-en-Y gastric bypass, which results in both restriction and absorption inhibition (Table 5). These surgeries are standard procedures that have already proven their effectiveness and safety,34 and since each surgical method has advantages and disadvantages, it is important to select an appropriate surgical method according to each patient’s situation. In addition, in order to secure the safety and efficiency of patient management before and after surgery, collaboration across various departments is essential.
Obesity in children and adolescents is rapidly increasing due to changes in diet, living environment, and decreases in physical activity. Obesity in children and adolescents is a chronic disease that is difficult to treat. It easily develops into adult obesity and requires a healthy diet and active lifestyle throughout life. Therefore, a policy of early detection and treatment should be established.
For the evaluation of obesity in children and adolescents, it is important to continuously evaluate obesity trends according to growth and development status through regular check-ups.35 The most widely used indicator is BMI. Percentile of BMI by sex and age is used to evaluate obesity in children and adolescents aged 2 years or older. In addition, since the growth and development period and body composition may differ depending on ancestry, standard values for Korean children and adolescents are applied. Age is calculated in months.35 Children or adolescents with BMI above the 85th percentile are considered overweight, those above the 95th percentile are obese, and those below the 85–95th percentile are regarded as pre-obesity.35
Considering the effects of obesity and obesity treatment on growth and development, it is important to prepare a treatment strategy for maintaining appropriate weight and avoiding unconditional weight loss.36-41 The key to the treatment of obesity in children and adolescents is to maintain an appropriate weight by inducing and continuing lifestyle modifications. Orlistat is the only drug approved by the U.S. Food and Drug Administration for usage by those over 12 years of age.42,43
Body weight is gained naturally with age and in the elderly, mortality does not increase with BMI ≥25 kg/m2. The mortality rate in the elderly population is influenced not only by weight but also by other variables such as comorbidities.44 Therefore, for the diagnosis of obesity in the elderly, it is recommended to measure WC together with BMI, and indicators such as the WC to height ratio and the WC to hip circumference ratio can also be utilized.45
Weight loss is recommended for elderly patients when it is judged that the benefits gained through weight loss during obesity treatment are greater than the harms. Even in the elderly, weight loss through lifestyle modifications such as diet control and physical activity is first considered and positive effects can be expected such as improving physical function and cardiovascular index.46
Well-designed studies of the effectiveness and safety of anti-obesity medications in the elderly are insufficient. Among drugs for obesity treatment approved for long-term use, orlistat can be safely used for elderly patients.47 Bariatric surgery in the elderly seems to be helpful for treating weight loss or diabetes,48,49 but caution is necessary because the risk of complications after surgery may increase.50
Metabolic syndrome is the term for a combination of metabolic abnormalities such as hyperglycemia, high blood pressure (hypertension) and obesity.51 Diagnosis criteria for metabolic syndrome are in the process of being integrated, as different organizations have different criteria. International Diabetes Federation criteria for diagnosing metabolic syndrome begin with the recognition of abdominal obesity as the most important etiology, and therefore, abdominal obesity is an essential requirement for diagnosing metabolic syndrome. In addition, one of the main features is that it is recommended to use WC measurements suitable for different groups in recognition that the diagnostic criteria for abdominal obesity may differ by ancestry. In 2007, based on the results of the National Health and Nutrition Survey, Korea recognized abdominal obesity when the WC was more than 90 cm for men and 85 cm for women,52 and a recent study found that this criterion was appropriate for Koreans. Diagnosis of metabolic syndrome in Korean adults requires ≥3 of the following five criteria: WC of ≥90 cm (men) or ≥85 cm (women), blood pressure ≥130/85 mmHg or taking anti-hypertensive medication, fasting blood glucose ≥100 mg/dL or taking anti-diabetic medication, triglycerides ≥150 mg/dL, and high-density lipoprotein cholesterol <40 mg/dL (men) or 50 mg/dL (women) or taking anti-dyslipidemia medication.
The goal of metabolic syndrome treatment is to prevent cardio-cerebrovascular diseases and diabetes. There are two major therapeutic approaches to metabolic syndrome. One is lifestyle modification to reduce insulin resistance, which is the cause of metabolic syndrome, and the other is pharmacotherapy for each component of metabolic syndrome.
Obesity is a disease associated with increased socioeconomic burden due to increased risk of obesity-related comorbidities. Since obesity is multifactorial, treatments for obesity include comprehensive lifestyle interventions such as nutrition therapy, physical activity, behavior therapy, and pharmacotherapy. The proper surgical management of obesity requires a multidisciplinary treatment team. This new guideline helps primary care physicians make safer and more effective decisions by providing evidence-based recommendations with clear evidence levels and high-quality evidence-based information. More efforts are needed to improve the quality of obesity treatment and management in Korea.
Ga Eun Nam has worked as an Associate Editor of the journal since 2020. However, she was not involved in the peer reviewer selection, evaluation, or decision process of this article. Otherwise, no other potential conflicts of interest relevant to this article were reported.
This work was supported by the Korean Society for the Study of Obesity.
Study concept and design: BYK and CHK; acquisition of data: SMK, JHK (Jee-Hyun Kang), SYK, KKK, and BK; analysis and interpretation of data: SJK, YHK, JHK (Jae Hyun Kim), HL, EJJ, SC, KBK, YAS and YHH; drafting of the manuscript: BYK and CHK; critical revision of the manuscript: BYK, EMK, SMK, JHK (Jee-Hyun Kang), SYK, KKK, BK, SJK, YHK, JHK (Jung-Hwan Kim), JHK (Jae Hyun Kim), GEN, JYP, JWS, HJS, TJO, HL, EJJ, SC, YHH, YAS and CHK; statistical analysis: SJK, YHK, and JHK (Jung-Hwan Kim); obtained funding: BYK and CHK; administrative, technical, or material support: BYK and CHK; and study supervision: CHK.
Levels of evidence and recommended grades
|Level of evidence|
|A||There is good research-based evidence to support the recommendation.
Data derived from at least 1 randomized controlled trial, meta-analysis or systematic review
|B||There is fair research-based evidence to support the recommendation.
Data derived from at least 1 well designed cohort or case-control study without randomization
|C||There is fair evidence but it is insufficient to support the recommendation.
Data derived from case series or observational studies
|D||The recommendation is based on expert opinion and panel consensus.
Consensus of expert opinions based on experience
|Class I||The recommendation is supported by level of evidence A.
Clinically important outcomes and the study population is representative of the population in the recommendation.
|Class IIa||The recommendation is supported by level of evidence B.
Clinically important or validated surrogate outcomes.
|Should be considered|
|Class IIb||The recommendation is supported by level of evidence C or D.
The outcome is an unvalidated surrogate condition but clinically important outcomes.
|May be considered|
|Class III||The recommendation is supported by level of evidence C or D.
Outcome is an unvalidated surrogate for clinically important population, or the applicability of the study is irrelevant.
|Is not recommended|
Data from Schünemann et al.3
Recommendations for the management of obesity
|Recommendation||Category of evidence and strength of recommendation|
|Evaluation before obesity treatment|
|1.||The definition for obesity in adults is BMI ≥ 25 kg/m2. Abdominal obesity is detected by measuring the waist circumference and is defined as ≥ 90 cm and ≥ 85 cm for adult men and women, respectively.||B, Class IIa|
|2.||Obesity is classified into primary obesity, commonly known as simple obesity, and secondary obesity, which can be caused by genetics, endocrine diseases, and drugs.||B|
|3.||Obesity increases the risk of type 2 diabetes, hypertension, dyslipidemia, coronary artery disease and metabolic syndrome, and increases total mortality, cancer mortality, and cardiovascular mortality.||A|
|4.||It is recommended that treatment is determined through sufficient discussion between the patient and physician about the benefits and risks associated with weight loss. While recommending treatments for obesity to patients, doctors must ensure that patients are ready to participate in weight loss.||C, Class I|
|5.||It is recommended to lose 5%–10% of body weight within 6 months after starting treatment as the primary goal of weight loss.||A, Class I|
|Nutrition therapy in obesity management|
|6.||In order to lose weight, it is recommended that energy intake should be reduced, and the degree of energy restriction should be individualized according to individual characteristics and medical conditions.||A, Class I|
|7.||Various dietary methods (low calorie diet, low carb diet, low fat diet, high protein diet) can be selected, but energy intake can be reduced, and nutritionally appropriate methods are recommended.||A, Class I|
|8.||It is recommended to individualize the composition of macronutrients (carbohydrates, fats, proteins) according to individual characteristics and medical conditions.||C, Class I|
|9.||Very-low calorie diet should be implemented only in limited circumstances, and intensive interventions are recommended to be carried out to improve lifestyles along with medical monitoring.||A, Class I|
|Physical activity in obesity management|
|10.||It is recommended to assess participation in physical activity and conduct health status evaluation before physical activity. In patients with symptoms of cardiovascular, metabolic, or kidney disease, it is recommended to start physical activity after consulting the patient’s doctor. Otherwise, low to moderate intensity of physical activity is recommended initially.||A, Class I|
|11.||For weight loss, it is recommended to perform aerobic exercise for at least 150 minutes per week or 3–5 times a week. Additional resistance training 2–4 times a week using large muscle groups should be considered to lose weight.||A, Class I A, Class IIa|
|12.||Physical activity alone does not have a great effect on weight loss, so we recommend physical activity combined with nutrition therapy.||A, Class I|
|13.||For weight loss, a combination of aerobic exercise and resistance exercise should be considered because it is more effective than aerobic exercise alone and resistance exercise alone. There is no significant difference between high-intensity exercise and moderate-intensity exercise in terms of weight loss effect.||A, Class IIa|
|Behavior therapy in obesity management|
|14.||For weight loss, it is recommended to improve lifestyle through interventions such as reducing food intake and increasing physical activity.||A, Class I|
|15.||For effective weight loss, it is recommended that a trained therapist performs behavior therapy for more than 6 months.||A, Class I|
|16.||For effective weight maintenance, it is recommended that a trained therapist performs behavioral therapy for at least 1 year.||A, Class I|
|17.||It is recommended that obese people be suspected to have eating disorders if they are observed with excessive weight or body type in self-assessment, various weight control behaviors to offset the effects of binge eating, or binge eating.||A, Class I|
|18.||In the case of behavioral therapy for weight loss, smoking cessation counseling should be performed.||B, Class IIa|
|19.||In the case of behavioral therapy for weight loss, we recommend alcohol counseling.||A, Class I|
|20.||For the treatment of sleep apnea, it is recommended to lose weight through behavioral therapy.||A, Class I|
|Pharmacotherapy in obesity management|
|21.||The basic treatments for obesity include nutrition therapy, physical activity, and behavior therapy, and we recommend pharmacotherapy as an additional treatment alongside comprehensive lifestyle intervention.||A, Class I|
|22.||In cases of failure to lose weight through lifestyle intervention in patients with BMI ≥ 25 kg/m2, pharmacotherapy should be considered.||B, Class IIa|
|23.||For long-term weight management, it is recommended that drugs approved based on the large-scaled clinical trials should be used.||B, Class I|
|24.||It is recommended that the pharmacotherapy be changed or discontinued if weight loss is not greater than 5% within 3 months of pharmacotherapy.||A, Class I|
|25.||Bariatric surgery should be considered to maintain weight loss and for weight loss in patients with severe obesity and to improve accompanying diseases related to obesity, including type 2 diabetes.||A, Class IIa|
|26.||Bariatric surgery should be considered in patients with failure to lose weight despite optimal medical and behavioral management in whom with BMI ≥ 35 kg/m2 or BMI ≥ 30 kg/m2 and obesity-related comorbidities.||B, Class IIa|
|27.||Bariatric surgery should be considered in patients with type 2 diabetes with BMI ≥ 27.5 kg/m2 or poorly controlled blood glucose despite optimal medical management.||B, Class IIa|
|28.||Sleeve gastrectomy, Roux-en-Y gastric bypass surgery, adjustable gastric band surgery, and biliopancreatic diversion surgery are standard procedures with established effectiveness and safety.||A, Class I|
|29.||Before surgery, it is recommended to obtain past medical and psychosocial history and perform physical examination and diagnostic test to evaluate the safety of the surgery.||A, Class I|
|30.||Preoperative micronutrient examination is required, and follow-up examination is recommended according to the schedule after the surgery||A, Class I|
|31.||Multidisciplinary treatment should be considered before and after surgery to increase the treatment effectiveness and safety.||C, Class IIa|
|Obesity in children and adolescents|
|32.||It is recommended to prevent and treat childhood and adolescent obesity because they often develop into adult obesity and can cause accompanying diseases.||A, Class I|
|33.||Treatment for childhood and adolescent obesity is recommended to provide the energy and nutrients needed for normal growth and main- tain appropriate weight with proper lifestyle modifications.||A, Class I|
|34.||When diagnosing obesity in children and adolescents over the age of 2, BMI percentiles by sex and age are based on the 2017 Child and Adolescent Growth Chart. BMI ≥ the 85th percentile is defined as pre-obesity, and ≥ the 95th percentile is defined as obesity.||A, Class I|
|35.||Individualized risk assessment should be considered in children and adolescents with pre-obesity or obesity.||B, Class IIa|
|36.||For the treatment of obesity in children and adolescents, comprehensive lifestyle interventions including nutrition therapy, physical activity, and behavior therapy are recommended.||A, Class I|
|37.||When comprehensive lifestyle interventions including nutrition therapy, physical activity, and behavior therapy fail to result in appropriate weight loss and comorbidities are not controlled, pharmacotherapy by an experienced specialist should be considered.||B, Class IIa|
|Obesity in the elderly|
|38.||For diagnosis of obesity in the elderly, it is recommended to evaluate waist circumference along with BMI.||A, Class I|
|39.||Weight loss in the elderly should be considered when the benefits of weight loss are greater than the status.||B, Class IIa|
|40.||In the treatment of obesity in the elderly, a protein-rich low-calorie diet and increased physical activity are recommended.||A, Class I|
|41.||In the treatment of obesity in the elderly, pharmacotherapy and surgical treatment may be considered with regard to individual comorbidities, other medications, and safety||B, Class IIb|
|42.||As the severity of obesity increases, the incidence of metabolic syndrome increases.||A|
|43.||The clinical significance of metabolic syndrome can predict the occurrence of diabetes and cardiovascular disease, and increases morbidity and mortality caused by cardiovascular disease||A|
|44.||Diagnosis of metabolic syndrome in adults in Korea requires ≥ 3 of the five following criteria: waist circumference ≥ 90 cm (men) or ≥ 85 cm (women), blood pressure ≥ 130/85 mmHg or taking anti-hypertensive medication, fasting blood glucose ≥ 100 mg/dL or taking anti-diabetic medication, triglycerides ≥ 150 mg/dL, HDL cholesterol < 40 mg/dL (men), or 50 mg/dL (women), or taking anti-dyslipidemia medication.||D|
|45.||For the treatment of metabolic syndrome, lifestyle intervention and treatment of each component should be considered.||A, Class IIa|
BMI, body mass index; HDL, high-density lipoprotein.
Definitions of obesity and risk of comorbidity according to obesity and abdominal obesity in Koreans
|Classification||Risk of comorbidity according to abdominal obesity|
|< 90 cm (men), < 85 cm (women)||≥ 90 cm (men), ≥ 85 cm (women)|
|Underweight ( < 18.5)||Low||Average|
|Class I obesity (25.0–29.9)||High||Severe|
|Class II obesity (30.0–34.9)||Severe||Very severe|
|Class III obesity ( ≥ 35.0)||Very severe||Very severe|
Pre-obesity may be defined as overweight or at-risk weight, and class III obesity may be defined as extreme obesity.
BMI, body mass index.
Individualization of anti-obesity medications
Types of bariatric surgery
|Type of surgery|
|Adjustable gastric banding||Sleeve gastrectomy||Roux-en-Y gastric bypass||Biliopancreatic diversion/Duodenal switch|
|History (yr)||30||10-15||50 (Most historical)||20|
|Surgical technique||Placement of an adjustable band to retain a small amount of gastric reservoir (15~20 mL)||Longitudinal resection of the stomach to achieve about 80% of gastric volume reduction||Creation of small gastric pouch (about 30 mL) with diversion of digestive pathway (bypassing the residual stomach and upper gastro-intestinal tract)||Sleeve gastrectomy with duodenal-ileal anastomosis (bypassing the entire jejunum and proximal part of ileum)|
|Mechanism of weight loss||Intake restriction||Intake restriction||Intake restriction (+ absorption restriction)||Intake restriction + absorption restriction|
|Reversibility||Reversible||Irreversible||Partially reversible||Partially reversible|
|Effect of weight loss (mid- to long-term %EWL*)||2 yr: 50%
10 yr: 40%
|2 yr: 60%
10 yr: 50%-55%†
|2 yr: 70%
10 yr: 60%
|2 yr: 70%-80%
10 yr: 70%
|Advantages and disadvantages, Complications||The frequency of implementation is decreasing because of relatively high incidence of visceral complications related to foreign material (30%–40% of band removal or revisional surgery is required within 10 years).||Occurrence or deterioration of gastro-esophageal reflux after surgery
Relatively high incidence of weight regain at long-term follow-up
|Difficulties in endoscopic screening of the bypassed stomach
Risk of dumping syndrome and marginal ulcer
Regular checkup and appropriate supplementation is required for prevention of trace element deficiency
|Depletion of protein and trace elements occurs frequently
Life-long supplementation of deficient nutrients is needed
*Percentage of EWL: the rate of loss of excess weight based on body mass index of 25 kg/m²; †Long-term follow-up data for more than 10 years is not yet sufficient.
EWL, excess weight loss.
Online ISSN : 2508-7576Print ISSN : 2508-6235
© Korean Society for the Study of Obesity.
Room 1010, Renaissance Tower Bldg., 14, Mallijae-ro, Mapo-gu, Seoul 04195, Korea.
Tel: +82-2-364-0886 Fax: +82-2-364-0883 E-mail: email@example.com
Powered by INFOrang Co., Ltd